Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia ( CLL2‐BCG ): Final analysis of a multicenter, open‐label phase‐II ‐trial
American Journal of Hematology · 2024
DOI: 10.1002/ajh.27304 ↗Kurz gefasst
Leserbrief in der Zeitschrift American Journal of Hematology, 2024. Verfasst von Paula Cramer und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department I of Internal Medicine and German CLL Study Group; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University o…. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Purines, Quinazolinones, Bendamustine Hydrochloride. Die Arbeit nennt 5 Literaturangaben. Gefördert von: F. Hoffmann-LaRoche, Gilead Sciences.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department I of Internal Medicine and German CLL Study Group; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Col…
- Clinic for Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
- Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany.
- Practice for Hematology and Oncology UnterEms, Leer, Germany.
- Practice for Hematology and Oncology Bethanien, Frankfurt/Main, Germany.
- Practice for Hematology and Oncology Pasing and Fürstenfeldbruck, Munich, Germany.
ORCID-Profile: Paula Cramer, Othman Al-Sawaf, Petra Langerbeins
Förderung
- F. Hoffmann-LaRoche
- Gilead Sciences
Zitieren
APA
Cramer, P., von Tresckow, J., Fink, A. M., Robrecht, S., Giza, A., Tausch, E., Müller, L., Knauf, W., Zingerle, M., Al-Sawaf, O., Langerbeins, P., Fischer, K., Kreuzer, K. A., Kneba, M., Wendtner, C. M., Stilgenbauer, S., Eichhorst, B., & Hallek, M. (2024). Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia ( CLL2‐BCG ): Final analysis of a multicenter, open‐label phase‐II ‐trial. American Journal of Hematology. https://doi.org/10.1002/ajh.27304
Vancouver
Cramer P, von Tresckow J, Fink AM, Robrecht S, Giza A, Tausch E, et al. Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia ( CLL2‐BCG ): Final analysis of a multicenter, open‐label phase‐II ‐trial. American Journal of Hematology. 2024. doi:10.1002/ajh.27304
BibTeX
@article{Cramer2024,
author = {Cramer, Paula and von Tresckow, Julia and Fink, Anna-Maria and Robrecht, Sandra and Giza, Adam and Tausch, Eugen and Müller, Lothar and Knauf, Wolfgang and Zingerle, Matthias and Al-Sawaf, Othman and Langerbeins, Petra and Fischer, Kirsten and Kreuzer, Karl-Anton and Kneba, Michael and Wendtner, Clemens-Martin and Stilgenbauer, Stephan and Eichhorst, Barbara and Hallek, Michael},
title = {Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia ( CLL2‐BCG ): Final analysis of a multicenter, open‐label phase‐II ‐trial},
journal = {American Journal of Hematology},
year = {2024},
doi = {10.1002/ajh.27304}
}
EUVIMED